Patents by Inventor Thomas Wickham
Thomas Wickham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101713Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: ApplicationFiled: October 9, 2023Publication date: March 28, 2024Applicant: Silver Creek Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Patent number: 11814443Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: GrantFiled: March 25, 2021Date of Patent: November 14, 2023Assignee: Silver Creek Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Publication number: 20230322951Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: ApplicationFiled: May 3, 2023Publication date: October 12, 2023Applicant: Silver Creek Pharmaceuticals, Inc.Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Patent number: 11697780Abstract: Endothermic fuel compositions comprising 50% or more by volume decahydronaphthalene, including cis-decahydronaphthalene, trans-decahydronaphthalene or a mixture thereof, for use as endothermic fuels in hypersonic vehicles and particularly for use in dual-mode ramjet or supersonic combustion ramjet air breathing engines. Methods for operating a ramjet or scram jet engine wherein the endothermic fuel is used for cooling the combustor and for combustion in the combustor.Type: GrantFiled: March 7, 2022Date of Patent: July 11, 2023Assignee: Reaction Systems, Inc.Inventors: Bradley Dean Hitch, David Thomas Wickham, Jeffrey Robert Engel, Jacquelyn Brett Lewis
-
Patent number: 11673970Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: GrantFiled: October 23, 2020Date of Patent: June 13, 2023Assignee: Silver Creek Pharmaceuticals, Inc.Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Publication number: 20210290682Abstract: Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.Type: ApplicationFiled: May 27, 2021Publication date: September 23, 2021Applicant: Rubius Therapeutics, Inc.Inventors: Thomas Wickham, Tiffany Fen-Yi Chen, Xuqing Zhang, Carolyn Sayre, Jordi Mata-Fink, Sivan Elloul, Billy Law, Lenka Hoffman, Kristian Eric Teichert, Shamael Rabia Dastagir
-
Patent number: 11111448Abstract: Endothermic fuel compositions comprising 50% or more by volume decahydronaphthalene, including cis-decahydronaphthalene, trans-decahydronaphthalene or a mixture thereof, for use as fuels in hypersonic vehicles and particularly for use in dual-mode ramjet or supersonic combustion ramjet air breathing engines.Type: GrantFiled: February 15, 2019Date of Patent: September 7, 2021Assignee: Reaction Systems Inc.Inventors: Bradley Dean Hitch, David Thomas Wickham, Jeffrey Robert Engel, Jacquelyn Brett Lewis
-
Publication number: 20210214463Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: ApplicationFiled: March 25, 2021Publication date: July 15, 2021Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Patent number: 10988547Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: GrantFiled: July 29, 2019Date of Patent: April 27, 2021Assignee: Silver Creek Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Publication number: 20210040233Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: ApplicationFiled: October 23, 2020Publication date: February 11, 2021Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Patent number: 10858450Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: GrantFiled: April 19, 2018Date of Patent: December 8, 2020Assignee: Silver Creek Pharmaceuticals, Inc.Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Publication number: 20200048368Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: ApplicationFiled: July 29, 2019Publication date: February 13, 2020Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Patent number: 10407512Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: GrantFiled: June 9, 2017Date of Patent: September 10, 2019Assignee: Silver Creek Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Publication number: 20180237540Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: ApplicationFiled: April 19, 2018Publication date: August 23, 2018Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Publication number: 20180223769Abstract: A system including a catalytic heat exchanger reactor configured to carry out exothermic decomposition of stable chemical species possessing positive heats of formation. In an embodiment, the reactor is configured to enhance decomposition reaction rates by contacting gas entering with a hot surface. The catalytic heat exchanger is configured to receive N2O and create N2 and O2. A torch is created by fuel together with the hot N2 and the O2. In an embodiment, the reactor is configured to, after an initial period of time, to allow a rapid transfer of products of the decomposition reaction into an engine. In an embodiment, the reactor is configured to enhance decomposition reaction rates by contacting gas entering with a hot surface, and the catalytic heat exchanger reactor is configured to promote the atomization and vaporization of liquid and gelled fuels with gas. Other embodiments are also disclosed.Type: ApplicationFiled: May 5, 2017Publication date: August 9, 2018Inventors: David Thomas Wickham, Bradley Dean Hitch, Jeffrey Robert Engel
-
Patent number: 9982060Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: GrantFiled: February 24, 2014Date of Patent: May 29, 2018Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Patent number: 9968694Abstract: The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique.Type: GrantFiled: November 1, 2016Date of Patent: May 15, 2018Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Thomas Wickham, Bart S. Hendriks, Samuel Agresta, Helen Lee, Daniel F. Gaddy
-
Patent number: 9913901Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.Type: GrantFiled: December 3, 2013Date of Patent: March 13, 2018Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Victor Moyo, Bart S. Hendriks, Thomas Wickham, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin
-
Publication number: 20170335015Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: ApplicationFiled: June 9, 2017Publication date: November 23, 2017Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Publication number: 20170258903Abstract: Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.Type: ApplicationFiled: May 18, 2017Publication date: September 14, 2017Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Christopher W. Espelin, Elena Geretti, Bart S. Hendriks, Victor Moyo, Joseph G. Reynolds, Thomas Wickham